← Back to Search

Interactive Software Therapy for Multiple Sclerosis and Cancer

N/A
Recruiting
Research Sponsored by Click Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to week 4
Awards & highlights

Study Summary

This trial tests a platform of interactive, software-based components that target key neural systems to improve health.

Who is the study for?
Adults aged 22-65 in the U.S. with Multiple Sclerosis, Lung or Breast Cancer who can use an app on a recent iPhone/Android device, follow study protocol, and have internet access. Excludes those with severe psychiatric/neurological disorders, recent hospitalization/study participation, hearing loss, substance abuse history or medication changes.Check my eligibility
What is being tested?
CT-100 platform's DiNaMo components are being tested for their potential therapeutic effects on neural systems related to various mental processes. The trial explores if these digital interventions can improve health outcomes for patients with specific conditions.See study design
What are the potential side effects?
Since CT-100 is software-based involving interactive components without drugs or invasive procedures, typical drug-related side effects are not expected. However, participants may experience discomfort from prolonged screen time or stress from engaging with the digital tasks.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to week 4
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to week 4 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Patient Reported Outcomes
Secondary outcome measures
Change in Pain Catastrophizing Scale
Change in Pain Severity and Pain Interference
Change in indication-specific measures Cancer
+3 more

Trial Design

8Treatment groups
Experimental Treatment
Group I: Oncology Lung Cancer Study App BExperimental Treatment1 Intervention
Cognitive Training App CT-100-D-004-B uses implicit training with verbal processing exercises to potentially redirect and modulate attention processes. This intervention is designed to help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli for lung cancer.
Group II: Oncology Lung Cancer Study App AExperimental Treatment1 Intervention
Cognitive Training App CT-100-D-004-A uses implicit training with audiovisual stimuli to potentially redirect and modulate attention processes. This intervention is designed to help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli for lung cancer.
Group III: Oncology Breast Cancer Study App BExperimental Treatment1 Intervention
Cognitive Training App CT-100-D-004-B uses implicit training with verbal processing exercises to potentially redirect and modulate attention processes. This intervention is designed to help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli for breast cancer.
Group IV: Oncology Breast Cancer Study App AExperimental Treatment1 Intervention
Cognitive Training App CT-100-D-004-A uses implicit training with audiovisual stimuli to potentially redirect and modulate attention processes. This intervention is designed to help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli for breast cancer.
Group V: Multiple Sclerosis without Mobility Limitations Study App BExperimental Treatment1 Intervention
Cognitive Training App CT-100-D-004-B uses implicit training with verbal processing exercises to potentially redirect and modulate attention processes. This intervention is designed to help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli for multiple sclerosis without mobility limitations.
Group VI: Multiple Sclerosis without Mobility Limitations Study App AExperimental Treatment1 Intervention
Cognitive Training App CT-100-D-004-A uses implicit training with audiovisual stimuli to potentially redirect and modulate attention processes. This intervention is designed to help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli for multiple sclerosis without mobility limitations.
Group VII: Multiple Sclerosis with Mobility Limitations Study App BExperimental Treatment1 Intervention
Cognitive Training App CT-100-D-004-B uses implicit training with verbal processing exercises to potentially redirect and modulate attention processes. This intervention is designed to help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli for multiple sclerosis with mobility limitations.
Group VIII: Multiple Sclerosis with Mobility Limitations Study App AExperimental Treatment1 Intervention
Cognitive Training App CT-100-D-004-A uses implicit training with audiovisual stimuli to potentially redirect and modulate attention processes. This intervention is designed to help improve cognitive capabilities as well as redirect attentional biases to make participants less sensitive to distressing stimuli for multiple sclerosis with mobility limitations.

Find a Location

Who is running the clinical trial?

Click Therapeutics, Inc.Lead Sponsor
15 Previous Clinical Trials
2,787 Total Patients Enrolled
Shaheen LakhanStudy DirectorClick Therapeutics
3 Previous Clinical Trials
283 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the protocol of this experiment allow for individuals below 40 years old to participate?

"This clinical trial stipulates a minimum age of 22 and a maximum age of 65 for potential participants."

Answered by AI

Is this research endeavor currently admitting new participants?

"Clinicaltrials.gov verifies that this clinical experiment, which was first advertised on October 19th 2023, is currently enlisting participants. The data has been most recently revised on November 13th of the same year."

Answered by AI

Is there any capacity for me to join this trial?

"The requirements for enrolment in this trial are that patients have a diagnosis of multiple sclerosis and fall within the age range of 22 to 65. This research project is recruiting approximately 180 participants."

Answered by AI

How many individuals are being considered for inclusion in the research trial?

"Yes, according to the information hosted on clinicaltrials.gov this trial—which was first made public on October 19th 2023—is presently looking for 180 participants at one location. The post has been updated as recently as November 13th 2023."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
An Exploratory Study to Evaluate Attention Biases in Adults With Multiple Sclerosis, Breast Cancer, and Lung Cancer
2023. "An Exploratory Study to Evaluate Attention Biases in Adults With Multiple Sclerosis, Breast Cancer, and Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06136923.
~120 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top